Edwards Lifesciences (NYSE:EW) had its price objective raised by equities research analysts at Raymond James from $160.00 to $175.00 in a research note issued on Thursday. The firm presently has an “outperform” rating on the medical research company’s stock. Raymond James’ price objective points to a potential upside of 9.18% from the company’s previous close.

EW has been the subject of a number of other research reports. Guggenheim lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Wednesday, September 26th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. SunTrust Banks lifted their target price on Edwards Lifesciences to $200.00 and gave the company a “buy” rating in a report on Friday, September 28th. Finally, Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. Edwards Lifesciences has an average rating of “Buy” and an average target price of $161.70.

EW stock traded up $2.94 during mid-day trading on Thursday, reaching $160.29. 27,183 shares of the company traded hands, compared to its average volume of 1,340,358. The company has a quick ratio of 1.85, a current ratio of 2.31 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $32.89 billion, a PE ratio of 42.18, a PEG ratio of 2.07 and a beta of 0.90. Edwards Lifesciences has a 52-week low of $110.68 and a 52-week high of $175.00.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. The business had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.84 EPS. On average, equities research analysts anticipate that Edwards Lifesciences will post 4.7 EPS for the current fiscal year.

In related news, Director Schack Wesley W. Von sold 1,319 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $160.96, for a total value of $212,306.24. Following the completion of the sale, the director now owns 2,134 shares in the company, valued at approximately $343,488.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $144.16, for a total value of $792,880.00. Following the completion of the sale, the vice president now owns 25,490 shares of the company’s stock, valued at approximately $3,674,638.40. The disclosure for this sale can be found here. Insiders sold a total of 183,356 shares of company stock valued at $27,011,207 in the last 90 days. 1.84% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in EW. Honkamp Krueger Financial Services Inc. bought a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $106,000. Private Capital Group LLC bought a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $112,000. Centaurus Financial Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $114,000. SRS Capital Advisors Inc. lifted its position in Edwards Lifesciences by 317.5% in the 3rd quarter. SRS Capital Advisors Inc. now owns 668 shares of the medical research company’s stock worth $116,000 after buying an additional 508 shares during the last quarter. Finally, TLP Group LLC lifted its position in Edwards Lifesciences by 163.6% in the 3rd quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock worth $118,000 after buying an additional 422 shares during the last quarter. Institutional investors own 82.55% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Compound Interest and Why It Matters When Investing

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.